

+

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Send to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

Complete if Known

Application Number	00/004,357
Filing Date	May 20, 1997
First Named Inventor	Pilon et al.
Group Art Unit	1640
Examiner Name	Romeo, D.
Attorney Docket Number	116142-00085

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

KL 3-2333085 ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/



Please use a plus sign (+) inside this box →



PTO/SB/06A (10-98)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

Application Number	08/064,367
Filing Date	May 26, 1997
First Named Inventor	Pilon, et al.
Group Art Unit	4646
Examiner Name	Romeo, D
Attorney Docket Number	116142-00085

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	ABMAN et al., "Pathophysiology and Treatment of Bronchopulmonary Dysplasia: Current Issues." Pediatric Clinics of North America, Vol. 41 No. 2, pp. 277-315 (1994).	
	CB	AKIYAMA et al., "Fibronectin and Integrins in Invasion..." Cancer and Metastasis Reviews. Vol. 14, pp. 173-189 (1995).	
	CC	ANDERSSON et al., "Heterologous Expression of Human Uteroglobin/Polychlorinated Biphenyl-binding Protein." J. Biol. Chem., Vol. 269 pp. 19081-19087 (1994).	
	CD	AOKI et al., "Isolation of Human Uteroglobin from Blood Filtrate." Mol. Hum. Reprod., Vol. 2, pp. 489-497 (1996).	
	CE	ASSMANN et al., "Familial Glomerulonephritis Characterized by Massive..." Am. J. Kid. Dis., Vol 25, pp. 781-791 (1995).	
	CF	BARNES et al., "Structural Basis for Calcium..." JMB, Vol. 256, pp. 392-404 (1996).	
	CG	BARTON et al., "Amino Acid Sequence Analysis of the..." Eur. J. Biochem., Vol. 198, pp. 749-760 (1991).	
	CH	BEIER, H.M., "Uteroglobin: A Hormone-dependent Endometrial Protein Involved in blastocyst Development," Biochem. Biophys. Acta, Vol. 180, pp. 280-291 (1968).	
	CI	BERENBAUM, F., "Phospholipase A2 inhibitors: a challenge for the future." Ref. Rhum. Engl. Ed., Vol. 62 pp. 409-14 (1995).	
	CJ	BERNARD, et al., "Serum Clara Cell Protein: An Indicator..." Env. Res., Vol. 66, pp. 96-104 (1994).	
	CK	BERNARD et al., "Clara Cell Protein in Serum and Bronchoalveolar Lavage." Eur. Respir. J. Vol. 5, pp. 1231-1238 (1992a).	

Examiner
SignatureDate
Considered¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please place a plus sign (+) inside this box → ☐

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	08/064,067
Filing Date	May 26, 1997
First Named Inventor	Pilon, et al.
Group Art Unit	4646
Examiner Name	Romeo, D
Attorney Docket Number	116142-00085

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CL	BERNARD et al., "Human Urinary Protein 1: Evidence for Identity with the Clara Cell Protein and Occurrence in Respiratory Tract and Urogenital Secretions," Clin. Chim. Act., Vol. 207, pp. 239-249 (1992b).	
	CM	BERNARD et al., "Selective Increase in the Urinary Excretion of Protein 1 (Clara Cell protein) and other low molecular weight proteins during normal pregnancy," Scand. J. Clin. Lab. Invest. Vol. 52, pp. 871-878 (1992c).	
	CN	BERNARD et al., "Protein 1 is a Secretory Protein for the Respiratory and Urogenital Tracts Identical to the Clara Cell Protein," Clin. Chem. Vol. 39, pp. 434-435 (1992d).	
	CO	BERNARD et al., "Determination by Latex Immunoassay of Protein 1 in Normal and Pathological Urine," Clin. Chem. Acta., Vol. 201, pp. 231-246 (1991).	
	CP	BERNARD et al., "Urine Protein 1: a Sex-Dependent Marker of Tubular or Glomerular Dysfunction," Clin. Chem. Vol. 35, pp. 2141-2142 (1989).	
	CQ	BITTERMAN et al., "Role of Fibronectin as a ...," J. Cell. Biol. Vol. 97 pp. 1925-1932 (1983).	
	CR	CAMUSSI et al., "Anti-inflammatory peptides (antiflammins) inhibit synthesis of platelet-activating factor, neutrophil aggregation, and chemotaxis, and intradermal inflammatory reactions," J. Exp. Med., Vol. 171, pp. 913-927 (1995a).	
	CS	CAMUSSI et al., "Antiflammins Inhibit Synthesis of Platelet-Activating ...," Biochem. Mol. Biol. and Physiol. of Phospholipase A2 and its Regulatory Factors, pp. 161-172 (1990).	
	CT	CHAN et al., "Antiflammins: Inhibit of Endotoxin-induced Uveitis in Lewis Rats," In Ocular Immunology Today (Usui, Ohno, and Aoki. Eds.), Elsevier Science Publishers, Amsterdam, pp. 467-470 (1990).	
	CU	CHAN et al., "Effects of Antiflammins on Endotoxin-Induced Uveitis in Rats," Arch. Ophthalmol., Vol. 109, pp. 278-281 (1991).	
	CV	CHIESA M et al., "Significant Increase in Immunoregulatory Protein Blastokinin/Uteroglobin in IgA/Fibronectin Complexes in Sera of Patients with IgA Nephropathy" Nephrology Dialysis Transplantation, Vol. 15, Mo. 9 p. A39 (2000).	
	CW	DERNIS et al., "Multiple forms of phospholipase A2 in macrophages capable of arachidonic acid release for docosanol biosynthesis," Adv. Prostaglandin Thromboxane Leukot Res., Vol. 23, pp. 75-80 (1995a).	

Examiner
Signature

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0851-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Application Number	08/004,567
Filing Date	May 20, 1997
First Named Inventor	Pilon, et al.
Group Art Unit	4646
Examiner Name	Romeo, D
Attorney Docket Number	116142-00085

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CX	DENNIS E.A., "Potential phospholipase A2s Involved in Inflammatory diseases," Agents Actions Suppl., Vol. 46, pp 35-39 (1995b).	
	CY	DHANIREDDY et al., "Ontogeny of Uteroglobin In Relation to...", "Pd. Res., 299A."	
	CZ	DIERYNCK et al., "The human Clara cell protein: biochemical and biological...", "Mult. Schler., Vol. 1, No. 8, pp. 385-387 (1996).	
	DA	EDELSON et al., "Acute Lung Injury Induced by Phospholipase A ₂ : Structural and Functional Changes," Am Rev. Respir. Dis., Vol. 143, pp 1102-1109 (1991).	
	DB	GUY et al., "Surfactant-producing Rabbit Pulmonary Alveolar Type II Cells...", "BBRC, Vol. 189, pp. 662-669 (1992).	
	DC	KIKUKAWA, et al., "Partial Characterization of a Uteroglobin-Like Protein in the Human Uterus and its Temporal Relationship to Prostaglandin Levels in This Organ," J. Clin. Endo & Met. 67(2): 315-321.	
	DD	LEYTON et al. "Recombinant Human Uteroglobin Inhibits the In Vitro Invasiveness...", "Cancer Res., Vol. 54 pp 3898-3899 (1994).	
	DE	MATTHEWS et al., "Crystallization and Characterization of the Recombinant Human Clara Cell 10-kDa Protein", PROTEINS: Structure, Function and Genetics, 20: 191-196 (1994).	
	DF	MUKHERJEE et al., "Modulation of Cellular Response to Antigens by Uteroglobin and Transglutaminase" Adv. Exp. Med. Biol., 231:135-152 (1988).	
	DG	MUKERJEE et al., "Regulation of Extracellular Phospholipase A2 Activity: Implication for Inflammatory Diseases" DNA and Cell Biology, Vol. 11, No. 3 pp. 233-243 (1992-04).	
	DH	MUKERJEE A B et al. "Could the Gene Coding for Human Uteroglobin (Clara Cell 10kDa Protein) be a candidate gene for Atopy?" American Journal of Human Genetics Vol. 55 No. 3 pA197 (1994).	
	DI	PERI et al., "Expression of Clara Cell 10-kD Gene in the Human Endometrium and Its Relationship to Ovarian Menstrual Cycle," DNA and Cell Biology, 13(5):495-503 (1994).	
	DJ	PERI A et al., "Uteroglobin Gene Expression in the Rabbit Uterus throughout gestation and in Fetal Lung: Relationship between Uteroglobin and Eicosanoid Levels in the Developing Fetal Lung," Journal of Clinical Investigation, Vol. 96, No. 1 pp 343-353 (1995).	
	DK	RENNARD et al., "Production of Fibronectin by the Human Alveolar Macrophage: Mechanism for the Recruitment of Fibroblasts to Sites of Tissue Injury in Interstitial Lung Diseases" Proc. Natl. Acad. Sci. USA, 78(11): 7147-7151 (1986).	
	DL	VADAS et al., "Potential therapeutic efficacy of inhibitors of...", Agents Actions, Vol. 19, pp. 194-202 (1988)."	

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-98)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 5

Complete If Known

Application Number	08/864,367
Filing Date	May 26, 1997
First Named Inventor	Pilon, et al.
Group Art Unit	1646
Examiner Name	Romeo, D
Attorney Docket Number	116142-00085

DM	VAN VYVE et al., "Protein content in bronchoalveolar lavage fluid of patients with asthma and control subjects", J. of Allergy and Clin. Immun., vol. 95 no. 1 pp. 60-68 (1995)	
DN	WATTS et al., "Effect of Dexamethasone Therapy on Fibronectin and Albumin Levels in Lung Secretions of Infants with Bronchopulmonary Dysplasia" J. Pediatr. 121:597-607 (1992).	
DO	ZHANG ZH et al., "Severe Fibronectin-Deposit Renal Glomerular Disease in Mice Lacking Uteroglobin." Science, Vol. 276, No. 5317 pp 1408-1412 (1997).	
DP	ZHANG ZH et al., "Human uteroglobin gene: Structure, subchromosomal localization and polymorphism", DNA and Cell Biology, vol. 16, no. 1 pp. 73-83 (1997).	

Examiner Signature	/David Romeo/ (06/07/2008)	Date Considered	
--------------------	----------------------------	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.